Urethral Cancer clinical trials at UCSF
1 research study open to eligible people
64Cu-GRIP B in Patients With Advanced Genitourinary Malignancies
open to eligible people ages 18 years and up
This is a first-in-human phase I/II imaging study of 64Cu-GRIP B PET in patients with advanced genitourinary (GU) malignancies. The tracer is designed to detect extracellular granzyme B as it is secreted by activated immune cells in the tumor microenvironment, which may highlight tumors that will regress on treatment with immunomodulatory therapies. The study population is focused on genitourinary malignancies, including renal cell and urothelial cancer, two tumor types with high mutational burden and tumor infiltrating lymphocytes compared to other tumor types, and have a predictable response rate at the population level to immune checkpoint inhibitors.
San Francisco, California
Our lead scientists for Urethral Cancer research studies include Rahul Aggarwal, MD.
Last updated: